Abstract
Purpose
Materials and Methods
Results
Conclusion
Notes
Ethical Statement
The study was approved by Institutional Review Board (IRB) of that Samsung Medical Center and informed consent were waived as we used di-identified data only (IRB no. SMC 2019-01-159-001).
Author Contributions
Concept and design: Shin DW, Cho JH, Zo JI, Cho J, Lee G, Shim YM.
Acquisition of data: Cho JH, Lee G, Shin S, Kim HK, Choi YS, Kim J, Zo JI, Shim YM.
Analysis and interpretation of data: Shin DW, Cho JH, Yoo JE, Cho J, Yoon DW, Shin S, Kim HK, Choi YS, Kim J, Zo JI, Shim YM.
Drafting the manuscript; Shin DW, Yoo JE, Lee G.
Critical revision of the manuscript for important intellectual contents: Shin DW, Cho JH, Yoo JE, Cho J, Yoon DW, Lee G, Shin S, Kim HK, Choi YS, Kim J, Zo JI, Shim YM.
Statistical analysis: Shin DW, Yoo JE, Cho J.
Obtained funding: Shin DW, Shim YM.
Administrative, technical, or material support: Lee G, Shim YM.
Integrity of the data and the accuracy of the data analysis: Shim YM.
ACKNOWLEDGMENTS
References
Table 1
Cardiovascular disease includes a history of ischemic heart disease, heart failure, and cerebrovascular disease. Lung disease includes a history of chronic pulmonary obstructive disease, asthma, and diffuse interstitial lung disease. Numbers of each category might not sum up to the total number due to missing information: n=7,288 for smoking, n=8,592 for FEV1, n=6,173 for DLCO. DLCO, single-breath carbon monoxide diffusion capacity; FEV1, forced expiratory volume in 1 second; ICD-O-3, International Classification of Diseases for Oncology, 3rd edition; SD, standard deviation.
Table 2
Recurrence-free survival (%)a) | Overall survival (%) | Overall relative survival (%) | ||||
---|---|---|---|---|---|---|
|
|
|
||||
5 Years (95% CI) | 10 Years (95% CI) | 5 Years (95% CI) | 10 Years (95% CI) | 5 Years (95% CI) | 10 Years (95% CI) | |
Total | 65.5 (64.3–66.8) | 58.8 (57.0–60.5) | 72.7 (71.6–73.7) | 56.7 (55.2–58.1) | 79 (78.8–79.1) | 67.8 (67.6–68.0) |
|
||||||
Age (yr) | ||||||
|
||||||
20–49 | 70.1 (66.5–73.5) | 68.6 (64.8–72.1) | 85.7 (83.0–88.0) | 76.5 (72.8–79.9) | 88.3 (88.2–88.4) | 81.4 (81.2–81.5) |
|
||||||
50–59 | 69.3 (67.0–71.5) | 63.2 (60.1–66.2) | 82.4 (80.6–84.0) | 70.6 (67.9–73.1) | 84.4 (84.3–84.4) | 75.4 (75.4–75.5) |
|
||||||
60–64 | 68.5 (65.7–71.2) | 61.9 (58.0–65.6) | 75.1 (72.7–77.3) | 61.5 (58.2–64.7) | 80.3 (80.2–80.3) | 69.5 (69.4–69.6) |
|
||||||
65–69 | 63.4 (60.5–66.2) | 53.6 (49.0–57.9) | 66.6 (64.0–69.0) | 46.1 (42.7–49.5) | 74.3 (74.2–74.3) | 61.1 (60.9–61.2) |
|
||||||
≥ 70 | 56.0 (52.8–59.0) | 42.0 (35.1–48.7) | 57.9 (55.5–60.4) | 33.2 (29.8–36.7) | 71.2 (71.1–71.3) | 56.9 (56.8–57.1) |
|
||||||
Sex | ||||||
|
||||||
Male | 63.3 (61.8–64.9) | 57.3 (55.2–59.3) | 66.1 (64.8–67.4) | 50.1 (48.3–51.8) | 78.3 (78.2–78.5) | 66.9 (66.7–67.1) |
|
||||||
Female | 69.3 (67.1–71.5) | 61.1 (57.7–64.3) | 85.6 (84.1–87.0) | 70.6 (68.0–73.1) | 80.2 (80.0–80.4) | 69.6 (69.3–69.9) |
|
||||||
Histology (ICD-O-3) | ||||||
|
||||||
Adenocarcinoma | 66.4 (64.8–68.0) | 58.2 (55.6–60.7) | 80.0 (78.7–81.2) | 63.7 (61.6–65.7) | 79.7 (79.5–79.9) | 68.9 (68.7–69.1) |
|
||||||
Squamous cell carcinoma | 62.6 (60.2–64.9) | 56.8 (53.7–59.7) | 59.1 (57.0–61.1) | 43.3 (40.9–45.7) | 76.9 (76.7–77.2) | 64.9 (64.6–65.3) |
|
||||||
Large cell carcinoma | 49.3 (41.7–56.5) | 43.6 (35.0–51.9) | 47.8 (40.6–54.6) | 36.8 (29.6–44.0) | 77.9 (77.1–78.7) | 66.3 (65.1–67.4) |
|
||||||
Others/Mixed | 70.5 (66.1–74.5) | 67.3 (62.4–71.7) | 74.4 (70.5–78.0) | 63.5 (58.7–68.0) | 80.9 (80.3–81.5) | 70.7 (69.8–71.5) |
|
||||||
Stage at diagnosis | ||||||
|
||||||
I | 78.2 (76.7–79.6) | 71.2 (69.0–73.4) | 84.5 (83.4–85.6) | 69.6 (67.8–71.4) | 79.3 (79.1–79.4) | 68.3 (68.0–68.5) |
|
||||||
II | 50.6 (47.8–53.2) | 43.9 (40.4–47.4) | 58.0 (55.6–60.4) | 41.7 (38.8–44.5) | 78.3 (78.0–78.5) | 66.8 (66.4–67.2) |
|
||||||
III | 31.3 (28.0–34.5) | 26.5 (23.0–30.1) | 45.0 (41.8–47.9) | 27.4 (24.1–30.8) | 78.7 (78.3–79.1) | 67.5 (67.0–68.0) |
|
||||||
Year of diagnosis | ||||||
|
||||||
1994–1999 | 51.5 (46.7–56.1) | 46.7 (41.8–51.5) | 53.5 (49.0–57.8) | 39.03 (34.7–43.3) | 80.0 (79.5–80.5) | 69.3 (68.6–70.1) |
|
||||||
2000–2009 | 63.3 (61.4–65.2) | 56.6 (54.3–58.3) | 68.1 (66.4–69.8) | 53.7 (51.8–55.6) | 79.1 (78.9–79.3) | 68.0 (67.7–68.4) |
|
||||||
2010–2016 | 68.5 (66.6–70.3) | 78.0 (76.6–79.3) | 78.8 (78.6–79.0) | 67.6 (67.4–67.8) | ||
|
||||||
Smoking status | ||||||
|
||||||
Never smoker | 69.3 (67.2–71.3) | 60.9 (57.6–63.9) | 84.6 (83.1–86.0) | 70.3 (67.8–72.7) | 88.9 (88.8–88.9) | 77.9 (77.8–80.0) |
|
||||||
Ex-smoker | 62.9 (60.4–65.2) | 57.5 (54.0–60.8) | 66.2 (64.0–68.3) | 49.6 (46.6–52.5) | 74.6 (74.3–75.0) | 62.7 (62.2–63.2) |
|
||||||
Current smoker | 64.2 (61.7–66.7) | 58.5 (55.1–61.8) | 67.8 (65.6–69.9) | 50.8 (47.7–53.7) | 73.7 (73.3–74.0) | 61.5 (61.0–62.0) |
|
||||||
Comorbidities | ||||||
|
||||||
Hypertension | ||||||
|
||||||
No | 65.3 (63.8–66.8) | 58.5 (56.4–60.5) | 72.5 (71.2–73.8) | 57.8 (56.0–59.5) | 78.0 (77.8–78.2) | 67.5 (67.3–67.8) |
|
||||||
Yes | 66.0 (63.7–68.2) | 59.5 (56.2–62.7) | 73.1 (71.2–74.9) | 53.8 (51.0–56.6) | 80.6 (80.5–80.8) | 68.1 (67.9–68.4) |
|
||||||
Diabetes mellitus | ||||||
|
||||||
No | 65.8 (64.4–67.1) | 58.8 (56.9–60.6) | 73.9 (72.7–75.0) | 57.9 (56.3–59.5) | 79.9 (79.8–80.0) | 69.3 (69.1–69.4) |
|
||||||
Yes | 64.1 (60.5–67.4) | 59.2 (54.5–63.6) | 65.7 (62.6–68.6) | 48.9 (44.8–52.9) | 73.9 (73.4–74.3) | 59.8 (59.2–60.5) |
|
||||||
CVD | ||||||
|
||||||
No | 65.6 (64.3–66.9) | 58.9 (57.1–60.7) | 73.4 (72.3–74.4) | 57.6 (56.0–59.1) | 79.5 (79.3–79.6) | 68.5 (68.3–68.7) |
|
||||||
Yes | 64.3 (59.5–68.8) | 56.7 (48.2–64.2) | 65.7 (61.7–69.3) | 45.2 (39.1–51.1) | 74.4 (74.1–74.7) | 61.6 (61.2–62.0) |
|
||||||
Lung disease | ||||||
|
||||||
No | 65.9 (64.6–67.2) | 59.1 (57.2–60.8) | 74.0 (72.9–75.0) | 58.0 (56.5–59.5) | 80.2 (80.1–80.3) | 69.4 (69.2–69.6) |
|
||||||
Yes | 59.4 (54.0–64.4) | 55.9 (49.3–62.0) | 55.1 (50.4–59.5) | 36.1 (30.0–42.2) | 63.7 (62.9–64.5) | 45.8 (44.8–46.9) |
|
||||||
Preoperative pulmonary function | ||||||
|
||||||
FEV1 < 80% of predicted | ||||||
|
||||||
No | 66.2 (64.8–67.6) | 59.6 (57.7–61.5) | 74.9 (73.8–76.1) | 59.5 (57.9–61.1) | 81.1 (80.9–81.2) | 70.6 (70.4–70.8) |
|
||||||
Yes | 61.3 (58.2–64.4) | 53.8 (49.0–58.3) | 62.3 (59.5–64.9) | 80.3 (78.9–81.6) | 69.3 (69.1–69.6) | 54.2 (53.8–54.6) |
|
||||||
DLCO < 80% of predicted | ||||||
|
||||||
No | 69.5 (67.7–71.3) | 60.9 (56.8–64.7) | 80.3 (78.9–81.6) | 62.3 (59.2–65.2) | 86.5 (86.4–86.7) | 74.5 (74.2–74.7) |
|
||||||
Yes | 58.7 (54.2–62.9) | 54.8 (48.5–60.6) | 41.1 (34.1–48.0) | 41.1 (34.1–48.0) | 67.9 (67.3–68.5) | 53.5 (52.7–54.3) |